Ultraviolet index and racial differences in prostate cancer incidence and mortality

Cancer

Volumn 119, Issue 17, 2013, Pages 3195-3203

  Taksler, Glen B ^a   Cutler, David M ^b,c,d   Giovannucci, Edward ^e   Smith, Matthew R ^f   Keating, Nancy L ^g,h  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD UNIVERSITY   (United States)

^d NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

disparities; prostate cancer; survival; vitamins

Indexed keywords

VITAMIN D;

ADULT; ARTICLE; BODY MASS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CONTROLLED STUDY; ETHNICITY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; SEASONAL VARIATION; SOLAR RADIATION; ULTRAVIOLET RADIATION; UNITED STATES; VITAMIN BLOOD LEVEL; WELLBEING;

DISPARITIES; PROSTATE CANCER; SURVIVAL; VITAMINS;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SEER PROGRAM; SUNLIGHT; ULTRAVIOLET RAYS; UNITED STATES; VITAMIN D;

EID: 84882603259     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28127     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
3. US Census Bureau. Current Population Survey. Annual Social and Economic Supplement, 2003-2009. Accessed at http://www.census.gov/cps/data/ cpstablecreator.html. Access date: November 26, 2012.
4. Toner CD, Davis CD, Milner JA,. The vitamin D and cancer conundrum: aiming at a moving target. J Am Diet Assoc. 2010; 110: 1492-1500.
5. Davis CD,. Vitamin D and cancer: current dilemmas and future research needs. Am J Clin Nutr. 2008; 88 (2): 565S-569S.
6. Moan J, Porojnicu AC, Dahlback A, Setlow RB,. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc Natl Acad Sci USA. 2008; 105: 668-673.
7. Freedman DM, Looker AC, Chang S, Graubard BI,. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst. 2007; 99: 1594-1602.
8. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP,. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007; 85: 1586-1591.
9. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006; 96: 252-261.
10. Moreno J, Krishnan AV, Feldman D,. Molecular mechanisms mediating the anti-proliferative effects of vitamin D in prostate cancer. J Steroid Biochem Mol Biol. 2005; 97: 31-36.
11. Moreno J, Krishnan AV, Peehl DM, Feldman D,. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res. 2006; 26: 2525-2530.
12. Bao BY, Yeh SD, Lee YF,. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis. 2006; 27: 32-42.
13. Bao BY, Yao J, Lee YF,. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis. 2006; 27: 1883-1893.
14. Holick MF,. Vitamin D: a millennium perspective. J Cell Biochem. 2003; 88: 296-307.
15. Jones G,. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008; 88: 582S-586S.
16. Robsahm TE, Tretli S, Dahlback A, Moan J,. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control. 2004; 15: 149-158.
17. Lagunova Z, Porojnicu AC, Dahlback A, Berg JP, Beer TM, Moan J,. Prostate cancer survival is dependent on season of diagnosis. Prostate. 2007; 67: 1362-1370.
18. Hanchette CL, Schwartz GG,. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer. 1992; 70: 2861-2869.
19. Schwartz GG, Hanchette CL,. UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control. 2006; 17: 1091-1101.
20. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P,. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control. 2000; 11: 847-852.
21. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer. 2004; 108: 104-108.
22. Ahn J, Peters U, Albanes D, et al. Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008; 100: 796-804.
23. Travis RC, Crowe FL, Allen NE, et al. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol. 2009; 169: 1223-1232.
24. Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI,. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III Study (1988-2006). Cancer Res. 2010; 70: 8587-8597.
25. Beer TM, Ryan CW, Venner PM, et al. ASCENT Investigators. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007; 25: 669-674.
26. Marketwire. Novacea Announces Preliminary Findings From Data Analysis of Ascent-2 Phase 3 Trial. marketwire.com/press-release/novacea-announces- preliminary-findings-from-data-analysis-of-ascent-2-phase-3-trial-nasdaq-novc- 864465.htm. Accessed November 8, 2012.
27. Clemens TL, Adams JS, Henderson SL, Holick MF,. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet. 1982; 1: 74-76.
28. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
29. National Aeronautics and Space Administration. Erythemal UV Exposure. Total Ozone Mapping Spectrometer. toms.gsfc.nasa.gov/ery-uv/euv-v8.html. Accessed August 12, 2010.
30. Boscoe FP, Schymura MJ,. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer. 2006; 6: 264.
31. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov. 2011 Sub, Vintage 2009 Populations (2000-2009) Linked To County Attributes-Total US, 1969-2010 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2012, based on the November 2011 submission.
32. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40 (suppl 8): IV-3- IV-18.
33. Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying Cause of Death 1999-2010. wonder.cdc.gov/ucd-icd10.html. Access date September 12, 2010.
34. Area Resource File: 2009-2010. Rockville, MD: US Department of Health and Human Services, Health Resources and Services Administration, Bureau of Health Professions; 2010.
35. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Data. Atlanta, GA: US Department of Health and Human Services; 1984-2009. cdc.gov/brfss/annual-data/annual-data.htm. Access date: May 1, 2012.
36. Environmental Protection Agency. Experimental UV Index. EPA 430-F-94-019. Washington, DC: Environmental Protection Agency; 1994.
37. Herman JR, Celarier EA,. Erythemal Exposure Data Product. NASA Goddard Space Center. macuv.gsfc.nasa.gov/doc/erynotes.pdf. Accessed August 12, 2010.
38. Terushkin V, Bender A, Psaty EL, Engelsen O, Wang SQ, Halpern AC,. Estimated equivalency of vitamin D production from natural sun exposure versus oral vitamin D supplementation across seasons at two US latitudes. J Am Acad Dermatol. 2010; 62: 929.e1-929.e9.
39. National Climatic Data Center. Global Historical Climatology Network-Daily Version 2.92. ftp://ftp.ncdc.noaa.gov/pub/data/ghcn/daily/ghcnd- all.tar.gz. Accessed April 17, 2012.
40. Lund CC, Broder NC,. Estimation of areas of burns. Surg Gynecol Obstet. 1944; 79: 352-358.
41. Shui IM, Mucci LA, Kraft P, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012; 104: 690-699.
42. McCullough ML, Weinstein SJ, Freedman DM, et al. Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172: 21-35.
43. Nimptsch K, Platz EA, Willett WC, Giovannucci E,. Association between plasma 25-OH vitamin D and testosterone levels in men. Clin Endocrinol (Oxf). 2012; 77: 106-112.